An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics, and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed Following Previous Rituximab Therapy.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Dacetuzumab (Primary) ; Rituximab
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Genentech
- 14 Nov 2011 Actual end date Nov 2010 added as reported by ClinicalTrials.gov.
- 31 Mar 2010 Actual number of patients (22) added as reported by ClinicalTrials.gov record.
- 31 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.